Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe

Objective To assess the current medical practice in Europe regarding prenatal dexamethasone (Pdex) treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Design and methods A questionnaire was designed and distributed, including 17 questions collecting quantitative and qualitative data. Thirty-six medical centres from 14 European countries responded and 30 out of 36 centres were reference centres of the European Reference Network on Rare Endocrine Conditions, EndoERN. Results Pdex treatment is currently provided by 36% of the surveyed centres. The treatment is initiated by different specialties, that is paediatricians, endocrinologists, gynaecologists or geneticists. Regarding the starting point of Pdex, 23% stated to initiate therapy at 4–5 weeks postconception (wpc), 31% at 6 wpc and 46 % as early as pregnancy is confirmed and before 7 wpc at the latest. A dose of 20 µg/kg/day is used. Dose distribution among the centres varies from once to thrice daily. Prenatal diagnostics for treated cases are conducted in 72% of the responding centres. Cases treated per country and year vary between 0.5 and 8.25. Registries for long-term follow-up are only available at 46% of the centres that are using Pdex treatment. National registries are only available in Sweden and France. Conclusions This study reveals a high international variability and discrepancy in the use of Pdex treatment across Europe. It highlights the importance of a European cooperation initiative for a joint international prospective trial to establish evidence-based guidelines on prenatal diagnostics, treatment and follow-up of pregnancies at risk for CAH.

[1]  W. Huisinga,et al.  Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling. , 2021, European journal of endocrinology.

[2]  E. Vicaut,et al.  Exposure to glucocorticoids in the first part of fetal life is associated with insulin secretory defect in adult humans , 2020 .

[3]  A. van’t Westeinde,et al.  First Trimester DEX Treatment Is Not Associated with Altered Brain Activity During Working Memory Performance in Adults , 2020, The Journal of clinical endocrinology and metabolism.

[4]  H. Falhammar,et al.  Update on the Swedish Newborn Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency , 2020, International journal of neonatal screening.

[5]  M. Omar,et al.  Congenital adrenal hyperplasia: Does repair after two years of age have a worse outcome? , 2020, Journal of pediatric urology.

[6]  A. van’t Westeinde,et al.  First-Trimester Prenatal Dexamethasone Treatment Is Associated With Alterations in Brain Structure at Adult Age , 2020, The Journal of clinical endocrinology and metabolism.

[7]  L. Karlsson,et al.  Perturbed Beta-Cell Function and Lipid Profile After Early Prenatal Dexamethasone Exposure in Individuals Without CAH , 2020, The Journal of clinical endocrinology and metabolism.

[8]  T. Hirvikoski,et al.  Cognitive Function of Children and Adolescents With Congenital Adrenal Hyperplasia: Importance of Early Diagnosis , 2020, The Journal of clinical endocrinology and metabolism.

[9]  Yanming Feng,et al.  Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA , 2019, Nature Medicine.

[10]  D. Gómez-Cabrero,et al.  Epigenetic Alterations Associated With Early Prenatal Dexamethasone Treatment , 2018, Journal of the Endocrine Society.

[11]  S. Rechitsky,et al.  Prenatal genetic testing and treatment for congenital adrenal hyperplasia. , 2019, Fertility and sterility.

[12]  M. New,et al.  Stigma Associated with Classical Congenital Adrenal Hyperplasia in Women’s Sexual Lives , 2017, Archives of Sexual Behavior.

[13]  T. Hirvikoski,et al.  Prenatal dexamethasone treatment in the context of at risk CAH pregnancies: Long-term behavioral and cognitive outcome , 2018, Psychoneuroendocrinology.

[14]  T. Hirvikoski,et al.  Evaluation of behavioral problems after prenatal dexamethasone treatment in Swedish children and adolescents at risk of congenital adrenal hyperplasia , 2018, Hormones and Behavior.

[15]  Zarko Alfirevic,et al.  Amniocentesis and chorionic villus sampling for prenatal diagnosis. , 2017, The Cochrane database of systematic reviews.

[16]  T. Hirvikoski,et al.  Cognitive impairment in adolescents and adults with congenital adrenal hyperplasia , 2017, Clinical endocrinology.

[17]  T. Hirvikoski,et al.  Sex-Dimorphic Effects of Prenatal Treatment With Dexamethasone. , 2016, The Journal of clinical endocrinology and metabolism.

[18]  M. Poli-Mérol,et al.  Should we question early feminizing genitoplasty for patients with congenital adrenal hyperplasia and XX karyotype? , 2016, Journal of pediatric surgery.

[19]  W. Miller.  Fetal endocrine therapy for congenital adrenal hyperplasia should not be done. , 2015, Best practice & research. Clinical endocrinology & metabolism.

[20]  P. Chatelain,et al.  Late prenatal dexamethasone and phenotype variations in 46,XX CAH: concerns about current protocols and benefits for surgical procedures. , 2014, Journal of pediatric urology.

[21]  Peiyong Jiang,et al.  Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. , 2014, The Journal of clinical endocrinology and metabolism.

[22]  N. Philip,et al.  New management strategy of pregnancies at risk of congenital adrenal hyperplasia using fetal sex determination in maternal serum: French cohort of 258 cases (2002-2011). , 2014, The Journal of clinical endocrinology and metabolism.

[23]  A. Bielawska,et al.  Cognitive and social function in girls with congenital adrenal hyperplasia — Influence of prenatally administered dexamethasone , 2014, Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence.

[24]  B. Khulan,et al.  Glucocorticoids as mediators of developmental programming effects. , 2012, Best practice & research. Clinical endocrinology & metabolism.

[25]  F. Beuschlein,et al.  Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. , 2012, European journal of endocrinology.

[26]  M. New,et al.  Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2012, European journal of endocrinology.

[27]  T. Hirvikoski,et al.  Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint. , 2012, The Journal of clinical endocrinology and metabolism.

[28]  K. Caldwell,et al.  A Predictable Worm: Application of Caenorhabditis elegans for Mechanistic Investigation of Movement Disorders , 2012, Neurotherapeutics.

[29]  T. Hirvikoski,et al.  Gender role behaviour in prenatally dexamethasone‐treated children at risk for congenital adrenal hyperplasia – a pilot study , 2011, Acta paediatrica.

[30]  D. Coplen.  Sexual Function and Surgical Outcome in Women with Congenital Adrenal Hyperplasia Due to CYP21A2 Deficiency: Clinical Perspective and the Patients' Perception , 2011 .

[31]  T. Hirvikoski,et al.  Long-term outcome of prenatal dexamethasone treatment of 21-hydroxylase deficiency. , 2011, Endocrine development.

[32]  V. Montori,et al.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. , 2010, The Journal of clinical endocrinology and metabolism.

[33]  T. Hirvikoski,et al.  Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems? , 2008, European journal of endocrinology.

[34]  T. Hirvikoski,et al.  Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. , 2007, The Journal of clinical endocrinology and metabolism.

[35]  C. Bouvattier,et al.  Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. , 2007, The Journal of clinical endocrinology and metabolism.

[36]  N. Hanley,et al.  The human fetal adrenal cortex and the window of sexual differentiation , 2006, Trends in Endocrinology & Metabolism.

[37]  P. White.  Ontogeny of adrenal steroid biosynthesis: why girls will be girls. , 2006, The Journal of clinical investigation.

[38]  David I. Wilson,et al.  In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. , 2006, The Journal of clinical investigation.

[39]  M. Forest.  Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2004, Human reproduction update.

[40]  M. New,et al.  Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. , 2004, The Journal of clinical endocrinology and metabolism.

[41]  C. Woodhouse,et al.  Genital sensation after feminizing genitoplasty for congenital adrenal hyperplasia: a pilot study , 2004, BJU international.

[42]  S. Pang.  Newborn screening for congenital adrenal hyperplasia. , 2003, Pediatric annals.

[43]  W. Miller,et al.  Consensus Statement on 21-Hydroxylase Deficiency from The European Society for Paediatric Endocrinology and The Lawson Wilkins Pediatric Endocrine Society , 2002, Hormone Research in Paediatrics.

[44]  M. New,et al.  EXTENSIVE PERSONAL EXPERIENCE: Prenatal Diagnosis for Congenital Adrenal Hyperplasia in 532 Pregnancies , 2001 .

[45]  B. Therrell.  Newborn screening for congenital adrenal hyperplasia. , 2001, Endocrinology and metabolism clinics of North America.

[46]  P. Speiser,et al.  Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. , 2001, Endocrinology and metabolism clinics of North America.

[47]  Hong-ying Huang,et al.  Uroplakin and androgen receptor expression in the human fetal genital tract: insights into the development of the vagina. , 2000, The Journal of urology.

[48]  S. Lajic,et al.  Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. , 1998, The Journal of clinical endocrinology and metabolism.

[49]  M. New,et al.  Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: Results of a pilot study , 1995, Psychoneuroendocrinology.

[50]  M. New,et al.  Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. , 1995, The Journal of clinical endocrinology and metabolism.

[51]  M. Forest,et al.  Prenatal diagnosis and treatment of 21-hydroxylase deficiency , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[52]  D. Shulman,et al.  Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. , 1992, The Journal of clinical endocrinology and metabolism.

[53]  M. Forest,et al.  Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. , 1989, Endocrine research.

[54]  M. Forest,et al.  Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. , 1984, The Journal of pediatrics.